Savant Capital LLC Grows Stock Holdings in Alkermes plc (NASDAQ:ALKS)

Savant Capital LLC lifted its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 11.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,075 shares of the company’s stock after acquiring an additional 1,152 shares during the quarter. Savant Capital LLC’s holdings in Alkermes were worth $319,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nicollet Investment Management Inc. increased its position in shares of Alkermes by 1.7% in the 3rd quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after purchasing an additional 714 shares during the last quarter. KBC Group NV lifted its stake in Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after purchasing an additional 774 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Alkermes by 3.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 30,950 shares of the company’s stock valued at $890,000 after purchasing an additional 897 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Alkermes by 17.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,956 shares of the company’s stock valued at $164,000 after acquiring an additional 904 shares in the last quarter. Finally, Archer Investment Corp increased its stake in Alkermes by 28.6% in the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock valued at $126,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on ALKS shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Alkermes in a research note on Tuesday, February 11th. They set a “buy” rating and a $40.00 price target on the stock. HC Wainwright restated a “neutral” rating and set a $46.00 price target on shares of Alkermes in a research note on Thursday, February 13th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and boosted their price target for the stock from $25.00 to $36.00 in a research note on Tuesday, November 5th. Finally, The Goldman Sachs Group upped their price target on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.25.

Alkermes Stock Performance

NASDAQ ALKS opened at $35.89 on Tuesday. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.25. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The firm has a 50-day moving average of $30.40 and a 200-day moving average of $28.81. The stock has a market cap of $5.81 billion, a PE ratio of 18.41, a P/E/G ratio of 1.83 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. On average, sell-side analysts anticipate that Alkermes plc will post 2.23 EPS for the current year.

Insider Buying and Selling

In other news, SVP Christian Todd Nichols sold 5,208 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now owns 60,703 shares in the company, valued at $1,769,492.45. This represents a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 323,608 shares of company stock worth $10,854,725 in the last ninety days. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.